Trastuzumab (Herceptin—anti HER2 monoclonal antibody mAb) has been shown to benefit breast and gastric cancer patients with HER2-amplification, but not in patients with endometrial or ovarian cancer [19,20,21]. This evidence concerns the gene ERBB2 and gastric cancer.